|
|
 |
|
Viewing report
|
|
|
|
Emerging Therapies to Treat Lupus Erythematosus
Decision Resources, Inc., Sep 2006, Pages: 23
Introduction
Lupus erythematosus (LE), a family of chronic autoimmune diseases, ranges from skin disease to life-threatening systemic disease. Multiple therapy options are necessary, even for patients with similar symptoms—and there is great need for agents that can control the complications of systemic disease. LE therapy development is increasing, and many companies are investigating LE as an expansion indication.
Get the Answers You Need to Shape Your Strategy
The small lupus erythematosus (LE) patient population poses challenges to companies that are developing agents for this indication: enrollment for clinical trials can be diffi cult, and the sales potential of these agents is limited. What are companies doing to surmount these challenges?
Although effective, few existing agents for cutaneous LE are considered safe enough for long-term use. An effective agent that is safe for prolonged treatment will have a signifi cant competitive advantage. Which agent now in development has the best chance to satisfy this need? Is any agent currently in development likely to displace current first-line therapies? Because of the heterogeneous nature of systemic LE, the market can support many agents. But owing to the number of effective generics available, emerging agents must prove their greater efficacy and safety to ensure adoption. What are the advantages and disadvantages of the emerging therapies’ modes of action? How soon are new therapies likely to reach the market? What are their prospects for success in competition with generics and established therapies?
Scope
Etiology, pathophysiology, and prevalence: relationship of cutaneous lupus erythematosus (CLE) to systemic lupus erythematosus (SLE); prevalence of systemic lupus erythematosus in the three major-market regions by gender.
Current therapies: overview of leading therapies for CLE and for SLE.
Indications covered: CLE (discoid LE), acute CLE, subacute CLE, and SLE.
Emerging therapies: overview of agents for development for CLE and SLE; late-stage agents are discussed in detail.
Market outlook: challenges that emerging agents will face and their prospects for success.
Therapies mentioned inside this report include:
- Abatacept
- Abetimus sodium
- Acitretin
- Amcinonide
- ASF-1096
- Azathioprine
- Belimumab
- Betamethasone
- diproprionate
- Celecoxib
- Chloroquine
- Clobetasol proprionate
- Cyclophosphamide
- Dapsone
- Difl orasone diacetate
- Edratide
- Efalizumab
- Epratuzumab
- Etretinate
- Hydroxychloroquine
- Intravenous gamma
- globulin
- Isotretinoin
- Lefl unomide
- Methotrexate
- Mycophenolate mofetil
- Pimecrolimus
- Prasterone
- Rituximab
- Sirolimus
- Tacrolimus
- Thalidomide
- Triamcinolone acetonide
Customers who bought this item also bought
Systemic Lupus Erythematosus: The Wait For Lupus-Specific Treatments
Stakeholder Opinions: Systemic Lupus Erythematosus - On the Verge of a Breakthough
The World Market for Addiction Disorders, 2005-2012: New Horizons in High-Profile Dependency Markets
Systemic Lupus Erythematosus: A Route to Other Autoimmune Disease
Patents in the Postgenomic Era: Proprietary Drug Targets and Therapies
Metabolic Diseases Pipeline Analysis:Focus on Dyslipidemia, Diabetes, and Obesity
Emerging Opportunities in Cancer Nanomedicine
Complementary Therapies and the Management of Diabetes and Vascular Disease: A Matter of Balance
|
|
|
|
